Navigation Links
Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System

MINNEAPOLIS, July 13 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,536,226 entitled, "Electro-Nerve Stimulator System and Methods." The patent covers the company's Urgent(R) PC system and stimulation methods for treatment of the overactive bladder ("OAB") symptoms of urinary urgency, urge incontinence and frequency of urinary voids.

The Urgent PC Neuromodulation System is a minimally invasive, office-based, nonsurgical system designed to deliver retrograde access to the sacral plexus through percutaneous electrical stimulation of the posterior tibial nerve. The Urgent PC system combines a pulse generator and a lead set to transfer electrical current from the pulse generator to the posterior tibial nerve, and includes a single use feature to prevent reuse of the lead set. By preventing reuse of lead sets, the Urgent PC System eliminates the health risks otherwise associated with re-using the same electrodes.

"We are very pleased that the United States Patent Office has awarded this patent on the unique features of our stimulation systems and methods," said David Kaysen, President and CEO. "This newly issued patent underscores our commitment to protect the unique features of the Urgent PC system. The system's ease of use and treatment effectiveness, coupled with a minimally invasive procedure and single-use features, are seen as key positives by our many clinical users as well as patients treated for the symptoms of OAB."

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms.

Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.

For more information about the Urgent PC Neuromodulation System, please call 866-277-0466 or visit

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder.

We also offer Macroplastique(R) Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. Forward-looking statements include statements about the scope of coverage and potential applications for Uroplasty's patents, whether Uroplasty's issued patents will be challenged and whether such challenges will have an adverse effect on the scope of the patents; whether Uroplasty will pursue enforcement of its issued patents or be successful in any such enforcement efforts; whether Uroplasty will successfully prosecute additional patent applications and if so, whether such applications will lead to the issuance of additional patents. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

    For Further Information:

    Uroplasty, Inc.                               EVC Group
    ---------------                               ---------
    David Kaysen, President and CEO, or           Doug Sherk (Investors)
    Medi Jiwani, Vice President, CFO, and         415.896.6820
    952.426.6140                                  Chris Gale (Media)

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results
2. Uroplasty to Issue Fourth Fiscal Quarter and Full Year Results on June 4, 2009
3. Uroplasty to Host Third Fiscal Quarter Conference Call on February 3
4. Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009
5. Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference
6. Uroplasty to Host First Quarter Conference Call on July 31
7. Uroplasty Joins the Russell Microcap Index
8. Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008
9. Uroplasty to Host Fourth Quarter and Year End Conference Call on June 3
10. Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annual Meeting
11. Uroplasty Plans to Double Sales Force During Fiscal 2009
Post Your Comments:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... has launched their Black Friday sale a week early, offering 40% off select ... transform the intimate apparel industry through both mobile fit technology and the latest ...
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), the ... Company as its newest Partner Firm. Based in Jefferson City, Missouri, their core ... advisor regardless of whether that client is a business, a family, or an ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... With Thanksgiving ... Insurance is sharing safety tips to help protect your family and vehicle. , According ... around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from ...
(Date:11/24/2015)... ... ... Dr. Rodney E. Willey , has answered a new calling – to relieve snoring ... treatment for snoring and sleep apnea through oral appliance therapy. He is ... in the US, one of four in the Illinois area. , Dr. Willey’s ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- Teledyne DALSA , a Teledyne Technologies company and ... its CMOS X-Ray detector for mammography at the ... 3, at McCormick Place in Chicago . ... imaging will be on display in the South Hall, Booth ... X-Ray detectors is the industry benchmark for high speed imaging ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation ... the Oppenheimer 26th Annual Healthcare Conference on December 8, ... Susie Lisa , vice president, Investor Relations, will ... analyst beginning at approximately 8:35 a.m. ET. --> ... participate in a 30-minute question-and-answer session with the host ...
(Date:11/24/2015)...   Renowned UAE nutritionist ... advice and insights on supplements and healthy diet ing ... of Dubai residents are not consuming enough ... femMED launches comprehensive solutions for women , s most ... residents are not consuming enough to keep themselves healthy. A local expert addressed ...
Breaking Medicine Technology: